The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years

Trends in Genetics

Volumn 33, Issue 12, 2017, Pages 960-970

  Baranzini, Sergio E ^a   Oksenberg, Jorge R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

gene regulatory networks; genetic pathways; GWAS; multiple sclerosis

Indexed keywords

MYELIN;

AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; ENDOPHENOTYPE; GENE MAPPING; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MULTIPLE SCLEROSIS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; PROCEDURES;

GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MULTIPLE SCLEROSIS; PHENOTYPE;

EID: 85030637475     PISSN: 01689525     EISSN: 13624555     Source Type: Journal    
DOI: 10.1016/j.tig.2017.09.004     Document Type: Review

References (93)

1. Hauser, S.L., Goodin, D.S., Multiple sclerosis and other demyelinating diseases. Longo, D.I., (eds.) Harrison's Principles of Internal Medicine, 19th edn, 2015, McGraw-Hill, 3395–3409.
2. Compston, A., Coles, A., Multiple sclerosis. Lancet 372 (2008), 1502–1517.
3. Hedstrom, A.K., et al. Environmental factors and their interactions with risk genotypes in MS susceptibility. Curr. Opin. Neurol. 29 (2016), 293–298.
4. Hedstrom, A.K., et al. Smoking is a major preventable risk factor for multiple sclerosis. Mult. Scler. 22 (2016), 1021–1026.
5. Olsson, T., et al. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat. Rev. Neurol. 13 (2017), 25–36.
6. Rhead, B., et al. Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol. Genet., 2, 2016, e97.
7. Sundqvist, E., et al. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. Mult. Scler. 20 (2014), 165–173.
8. Baxi, E.G., et al. Transfer of myelin-reactive th17 cells impairs endogenous remyelination in the central nervous system of cuprizone-fed mice. J. Neurosci. 35 (2015), 8626–8639.
9. Dendrou, C.A., et al. Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15 (2015), 545–558.
10. Devier, D.J., et al. Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro–inflammatory neurodegeneration. Front. Mol. Neurosci., 8, 2015, 5.
11. Yshii, L., et al. Neurons and T cells: understanding this interaction for inflammatory neurological diseases. Eur. J. Immunol. 45 (2015), 2712–2720.
12. Kappos, L., et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 87 (2016), 978–987.
13. Giovannoni, G., et al. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology 87 (2016), 1985–1992.
14. Hauser, S.L., et al. Ocrelizumab versus interferon β-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376 (2017), 221–234.
15. Blinkenberg, M., Soelberg Sorensen, P., Monoclonal antibodies for relapsing multiple sclerosis: a review of recently marketed and late-stage agents. CNS Drugs 31 (2017), 357–371.
16. Orton, S.M., et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 5 (2006), 932–936.
17. Sellner, J., et al. The increasing incidence and prevalence of female multiple sclerosis – a critical analysis of potential environmental factors. Autoimmun. Rev. 10 (2011), 495–502.
18. Koch-Henriksen, N., Sorensen, P.S., The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 9 (2010), 520–532.
19. Eskandarieh, S., et al. Multiple sclerosis epidemiology in East Asia, South East Asia and South Asia: a systematic review. Neuroepidemiology 46 (2016), 209–221.
20. Benito-Leon, J., Are the prevalence and incidence of multiple sclerosis changing?. Neuroepidemiology 36 (2011), 148–149.
21. Dilokthornsakul, P., et al. Multiple sclerosis prevalence in the United States commercially insured population. Neurology 86 (2016), 1014–1021.
22. Rosati, G., The prevalence of multiple sclerosis in the world: an update. Neurol. Sci. 22 (2001), 117–139.
23. Wallin, M.T., et al. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann. Neurol. 55 (2004), 65–71.
24. Wallin, M.T., et al. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain 135 (2012), 1778–1785.
25. Langer-Gould, A., et al. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology 80 (2013), 1734–1739.
26. Weinstock-Guttman, B., et al. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult. Scler. 9 (2003), 293–298.
27. Cree, B.A., et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 63 (2004), 2039–2045.
28. Willer, C.J., et al. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 12877–12882.
29. Hansen, T., et al. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult. Scler. 11 (2005), 504–510.
30. Kuusisto, H., et al. Concordance and heritability of multiple sclerosis in Finland: study on a nationwide series of twins. Eur. J. Neurol. 15 (2008), 1106–1110.
31. Robertson, N.P., et al. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain 119 (1996), 449–455.
32. Westerlind, H., et al. Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden. Brain 137 (2014), 770–778.
33. Ebers, G.C., Genetic factors in multiple sclerosis. Neurol. Clin. 1 (1983), 645–654.
34. Ebers, G.C., et al. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 377 (1995), 150–151.
35. Sawcer, S., The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 131 (2008), 3118–3131.
36. Haines, J.L., et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat. Genet. 13 (1996), 469–471.
37. Ebers, G.C., et al. A full genome search in multiple sclerosis. Nat. Genet. 13 (1996), 472–476.
38. Sawcer, S., et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat. Genet. 13 (1996), 464–468.
39. Ligers, A., et al. Evidence of linkage with HLA-DR in DRB1*15-negative families with multiple sclerosis. Am. J. Hum. Genet. 69 (2001), 900–903.
40. Sawcer, S., et al. A high-density screen for linkage in multiple sclerosis. Am. J. Hum. Genet. 77 (2005), 454–467.
41. International Multiple Sclerosis Genetics Consortium, Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357 (2007), 851–862.
42. Jakkula, E., et al. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am. J. Hum. Genet. 86 (2010), 285–291.
43. Comabella, M., et al. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One, 3, 2008, e3490.
44. Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat. Genet. 41 (2009), 824–828.
45. Baranzini, S.E., et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum. Mol. Genet. 18 (2009), 767–778.
46. De Jager, P.L., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 41 (2009), 776–782.
47. Consortium, I.M.S.G., et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476 (2011), 214–219.
48. Beecham, A.H., et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 45 (2013), 1353–1360.
49. Patsopoulos, N., et al. The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility. bioRxiv, 2017, 2017, 143933.
50. −8 has emerged as a standard of statistical significance for genome-wide association studies. J. Clin. Epidemiol. 68 (2015), 460–465.
51. Panagiotou, O.A., et al. What should the genome-wide significance threshold be? Empirical replication of borderline genetic associations. Int. J. Epidemiol. 41 (2012), 273–286.
52. Gourraud, P.A., et al. Aggregation of multiple sclerosis genetic risk variants in multiple and single case families. Ann. Neurol. 69 (2011), 65–74.
53. De Jager, P.L., et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol. 8 (2009), 1111–1119.
54. Isobe, N., et al. An ImmunoChip study of multiple sclerosis risk in African Americans. Brain 138 (2015), 1518–1530.
55. Langefeld, C.D., et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat. Commun., 8, 2017, 16021.
56. Roadmap Epigenomics Consortium, Integrative analysis of 111 reference human epigenomes. Nature 518 (2015), 317–330.
57. Maier, L.M., et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet., 5, 2009, e1000322.
58. Gregory, S.G., et al. Interleukin 7 receptor α chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 39 (2007), 1083–1091.
59. Galarza-Munoz, G., et al. Human epistatic interaction controls IL7R splicing and increases multiple sclerosis risk. Cell 169 (2017), 72–84.
60. Gregory, A.P., et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488 (2012), 508–511.
61. Alcina, A., et al. Tag-SNP analysis of the GFI1-EVI5-RPL5-FAM69 risk locus for multiple sclerosis. Eur. J. Hum. Genet. 18 (2010), 827–831.
62. Didonna, A., et al. A non-synonymous single-nucleotide polymorphism associated with multiple sclerosis risk affects the EVI5 interactome. Hum. Mol. Genet. 24 (2015), 7151–7158.
63. Hoppenbrouwers, I.A., et al. EVI5 is a risk gene for multiple sclerosis. Genes Immun. 9 (2008), 334–337.
64. Martin, D., et al. Genome-wide CTCF distribution in vertebrates defines equivalent sites that aid the identification of disease-associated genes. Nat. Struct. Mol. Biol. 18 (2011), 708–714.
65. Steri, M., et al. Overexpression of the cytokine BAFF and autoimmunity risk. N. Engl. J. Med. 376 (2017), 1615–1626.
66. Ascherio, A., Munger, K.L., Epidemiology of multiple sclerosis: from risk factors to prevention ​– an update. Semin. Neurol. 36 (2016), 103–114.
67. Amato, M.P., et al. Environmental modifiable risk factors for multiple sclerosis: report from the 2016 ECTRIMS focused workshop. Mult. Scler., 2017, 10.1177/1352458516686847 Published online January 6, 2017.
68. Ebers, G., Interactions of environment and genes in multiple sclerosis. J. Neurol. Sci. 334 (2013), 161–163.
69. Hedstrom, A.K., et al. The interaction between smoking and HLA genes in multiple sclerosis: replication and refinement. Eur. J. Epidemiol., 2017, 10.1007/s10654-017-0250-2 Published online June 8, 2017.
70. Lu, M., et al. Logistic principal component analysis for rare variants in gene-environment interaction analysis. IEEE/ACM Trans. Comput. Biol. Bioinform. 11 (2014), 1020–1028.
71. Consortium, E.P., The ENCODE (ENCyclopedia Of DNA Elements) project. Science 306 (2004), 636–640.
72. Consortium, E.P., An integrated encyclopedia of DNA elements in the human genome. Nature 489 (2012), 57–74.
73. Stunnenberg, H.G., et al. The International Human Epigenome Consortium: a blueprint for scientific collaboration and discovery. Cell 167 (2016), 1145–1149.
74. Horikoshi, M., et al. Genome-wide associations for birth weight and correlations with adult disease. Nature 538 (2016), 248–252.
75. Lamparter, D., et al. Fast and rigorous computation of gene and pathway scores from SNP-based summary statistics. PLoS Comput. Biol., 12, 2016, e1004714.
76. Baranzini, S.E., et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum. Mol. Genet. 18 (2009), 2078–2090.
77. Baranzini, S.E., The genetics of autoimmune diseases: a networked perspective. Curr. Opin. Immunol. 21 (2009), 596–605.
78. Gustafsson, M., et al. A validated gene regulatory network and GWAS identifies early regulators of T cell-associated diseases. Sci. Transl. Med., 7, 2015, 313ra178.
79. Rossin, E.J., et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet., 7, 2011, e1001273.
80. Wang, L., et al. PINBPA: cytoscape app for network analysis of GWAS data. Bioinformatics 31 (2015), 262–264.
81. Wang, L., et al. iPINBPA: an integrative network-based functional module discovery tool for genome-wide association studies. Pac. Symp. Biocomput. 2015 (2015), 255–266.
82. Campbell, R.D., Trowsdale, J., Map of the human MHC. Immunol. Today 14 (1993), 349–352.
83. Opelz, G., Lenhard, V., Immunological factors influencing renal graft survival. Annu. Rev. Med. 34 (1983), 133–144.
84. Chapman, S.J., Hill, A.V., Human genetic susceptibility to infectious disease. Nat. Rev. Genet. 13 (2012), 175–188.
85. Tsai, S., Santamaria, P., MHC class II polymorphisms, autoreactive T-cells, and autoimmunity. Front. Immunol., 4, 2013, 321.
86. Bertrams, J., et al. HL-A antigens and multiple sclerosis. Tissue Antigens 2 (1972), 405–408.
87. Hollenbach, J.A., Oksenberg, J.R., The immunogenetics of multiple sclerosis: a comprehensive review. J. Autoimmun. 64 (2015), 13–25.
88. Barcellos, L.F., et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. 72 (2003), 710–716.
89. Isobe, N., et al. Association of HLA genetic risk burden with disease phenotypes in multiple sclerosis. JAMA Neurol. 73 (2016), 795–802.
90. Patsopoulos, N.A., et al. Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet., 9, 2013, e1003926.
91. Moutsianas, L., et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat. Genet. 47 (2015), 1107–1113.
92. Welter, D., et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42:Database issue (2014), D1001–D1006.
93. Shannon, P., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13 (2003), 2498–2504.